Interestingly, a triple combination of anti-CTLA-4 + anti-PD-1 + radiotherapy induced complete responses in mouse pancreatic cancer and melanoma models, not seen with dual-checkpoint blockade alone (13). This evidence concerns the gene RPL17 and melanoma.